ATLANTIC BONE SCREEN
keyboard_backspaceBack to Home
Contact
3 rue Aronnax
44800 SAINT HERBLAIN
France
DIR COMMERCIALE
About us
Atlantic Bone Screen is a leading CRO (« Contract Research Organization ») specialized in high-quality preclinical evaluation services /non clinical studies in the field of bone and joint diseases, tumoral or non tumoral pathologies.
Created in 2005 by Ronan LE BOT, CEO, Atlantic Bone Screen puts at your disposal a unique preclinical platform with a wide range of competitive in-vitro and in-vivo assays as well as histology and imaging services.
More than 1500 preclinical studies have been conducted by Atlantic Bone Screen since its creation.
Research centers from the most important pharmaceutical and food industries as well as biomaterial companies have put their trust in Atlantic Bone Screen. The company belongs to the network of biotechnology companies of the Atlanpole Biotherapies cluster. Therefore Atlantic Bone Screen has many partners and consultants providing complementary services.
Atlantic Bone Screen is a registered service provider for research tax credit “CIR agreement” from the French Ministry of Research.
Business offer
Atlantic Bone Screen aims to optimize and accelerate the development of your compounds, allowing you to identify and characterize the therapeutic potential of your drug candidates, nutraceuticals and biomaterials.
Quality, Responsiveness and Innovation are our focus to answer our Partners and Customers preclinical needs and always to provide efficient support and high value-added services.
We can rely on several platforms and robust preclinical models:
- - In vitro assays on soteoclasts, osteoblasts, macrophages, fibroblasts, chondrocytes, tumoral cell lines…
- - in vivo models in our historical field of expertise, ie bone and joint diseases (osteoporosis, arthritis), bone cancer/metastases, biocompatibility tests…
- - Histology/Histopathology on any kind of tissues, either on samples from our studies or on samples received from our Customers : inflammation, neurology, oncology, dermatology...
- - Imaging services such as MicroCT analyses - Biomarkers analyses
Activities
- Service
- Oncology
- Immunology
- Inflammation
- Target selection & validation
- Expression and pathway analysis of target
- quantification of target
- Assay development in in-vitro & in-vivo models
- Hit discovery
- Screening & Identification
- In-vivo models
- In-vitro & ex-vivo models
- Immunotherapy lead generation
- Potency & Specificity
- Functional effects
- Pharmacology & Biological activity
- PK/PD bioavailability
- Mode of Action
- Therapeutic efficacy
- Immunotherapy lead optimization
- Proof of concept
- Pharmacology potency
- Exploratory toxicology
- in-vitro & ex-vivo models
- in-vivo models
- Preclinical biomarkers
- Mechanism/Function
- Mechanism of action
- PK/PD features
- Exploratory toxicology
- Level of response duration
- Specificity
- Surrogate markers
- Predictive biomarkers
- Treatment efficacy
- Population stratification
- Disease progression / follow-up
- Clinical biomarkers
- Predictive biomarkers
- Treatment efficacy
- Population stratification
- Disease progression / follow-up
- PK/PD features
- Surrogate markers
- Disease progression monitoring
- Companion biomarkers
- Pharmacology
- Treatment efficacy
- Toxicity
- Cell origin
- Single donor
- Pool of donors
- Cell Banking
- IPs
- MSC
- Tissue acquisition
- Target cell isolation
- Differentiated Cell
- Cell modification
- Cell Activation
- Ex Vivo & In Vivo Strategy
- Ex Vivo & In Vivo Strategy
- Target Identification
- Expression and pathway analysis of target
- quantification of target
- Assay development in in-vitro & in-vivo models
- Adoptive T Cell Major Challenges in Solid Tumors
- In vivo proliferation and activation of CAR-T
- Ex Vivo & In Vivo Strategy
- Ex Vivo & In Vivo Strategy
